Postnatal corticosteroids and neurodevelopmental outcomes in extremely low birthweight or extremely preterm infants: 15-year experience in Victoria, Australia
Jeanie Ling Cheong, Peter Anderson, Gehan Roberts, Julianne Duff, Lex W Doyle
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION | BMJ PUBLISHING GROUP | Published : 2013
OBJECTIVE: Postnatal corticosteroids (PCS) are used to prevent or treat bronchopulmonary dysplasia (BPD) in extremely low birthweight (ELBW; <1000 g) or extremely preterm (EPT; <28 weeks) infants. In the early 2000s, concerns were raised about increased risks of cerebral palsy (CP) in association with PCS, which may have affected prescribing of PCS, and influenced rates of BPD, mortality or long-term neurosensory morbidity. Our aim was to determine the changes over time in the rates of PCS use and 2-year outcomes in ELBW/EPT infants in Victoria, Australia. DESIGN: All ELBW or EPT infants born in Victoria, Australia in three distinct eras (1991-92, 1997 and 2005) who were alive at 7 days were..View full abstract
NHMRC project grants.